Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Recruiting

Phase 1

Phase 2

Zilovertamab VedotinSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06395103

Conditions

B-cell Acute Lymphoblastic Leukemia

Diffuse Large B-cell Lymphoma

Burkitt Lymphoma

Neuroblastoma

Ewing Sarcoma

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Interventions

Zilovertamab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-11-24.